PT1246638E - Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia - Google Patents

Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia

Info

Publication number
PT1246638E
PT1246638E PT01900978T PT01900978T PT1246638E PT 1246638 E PT1246638 E PT 1246638E PT 01900978 T PT01900978 T PT 01900978T PT 01900978 T PT01900978 T PT 01900978T PT 1246638 E PT1246638 E PT 1246638E
Authority
PT
Portugal
Prior art keywords
ipertrigliceridemia
exendinas
agonists
treatment
exendin
Prior art date
Application number
PT01900978T
Other languages
English (en)
Inventor
Andrew A Young
Orville Gene Kolterman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22639978&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1246638(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of PT1246638E publication Critical patent/PT1246638E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT01900978T 2000-01-10 2001-01-09 Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia PT1246638E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17536500P 2000-01-10 2000-01-10

Publications (1)

Publication Number Publication Date
PT1246638E true PT1246638E (pt) 2004-12-31

Family

ID=22639978

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01900978T PT1246638E (pt) 2000-01-10 2001-01-09 Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia

Country Status (12)

Country Link
US (1) US20030036504A1 (pt)
EP (1) EP1246638B2 (pt)
JP (1) JP2003519667A (pt)
AT (1) ATE275967T1 (pt)
AU (1) AU2006202247A1 (pt)
CA (1) CA2396157A1 (pt)
DE (1) DE60105547T3 (pt)
DK (1) DK1246638T4 (pt)
ES (1) ES2227115T5 (pt)
HK (1) HK1050477A1 (pt)
PT (1) PT1246638E (pt)
WO (1) WO2001051078A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304864T1 (de) * 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
DE60114996T2 (de) * 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
AU2005211776B2 (en) 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US20060190425A1 (en) * 2005-02-24 2006-08-24 Yuan-Chi Chang Method for merging multiple ranked lists with bounded memory
EP2455072A1 (en) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2007005738A2 (en) 2005-06-30 2007-01-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
KR101399178B1 (ko) * 2005-08-11 2014-06-18 아스트라제네카 파마수티컬스 엘피 선별가능한 특성을 갖는 하이브리드 폴리펩티드
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
HUE064811T2 (hu) 2005-08-19 2024-04-28 Amylin Pharmaceuticals Llc Extendin diabétesz kezelésében és testtömeg csökkentésében történõ alkalmazásra
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2009043479A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
RU2010113997A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Тиролиберин для терапевтического применения
EP2303313B1 (en) * 2008-05-21 2015-10-28 Amylin Pharmaceuticals, LLC Exendins to lower cholestrol and triglycerides
JP5622725B2 (ja) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
RU2521291C2 (ru) 2008-06-25 2014-06-27 Эндо Фармасьютикалз Солюшнз Инк. Имплантат октреотида, содержащий высвобождающее вещество
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
EP2654767A4 (en) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP6948330B2 (ja) 2015-12-23 2021-10-13 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ−１アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法
WO2018071528A1 (en) * 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CA3047862A1 (en) * 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
US20220152154A1 (en) 2019-03-08 2022-05-19 Amgen Inc. Growth differentiation factor 15 combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ATE304864T1 (de) * 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
NZ502874A (en) * 1997-12-12 2004-03-26 Warner Lambert Co Antihyperlipidemic statin-lp(a) inhibitor combinations
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
NZ514916A (en) * 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers

Also Published As

Publication number Publication date
ATE275967T1 (de) 2004-10-15
EP1246638B1 (en) 2004-09-15
AU2638001A (en) 2001-07-24
DE60105547D1 (de) 2004-10-21
WO2001051078A1 (en) 2001-07-19
ES2227115T5 (es) 2014-10-30
EP1246638B2 (en) 2014-07-30
ES2227115T3 (es) 2005-04-01
JP2003519667A (ja) 2003-06-24
DE60105547T2 (de) 2005-10-13
CA2396157A1 (en) 2001-07-19
DK1246638T4 (da) 2014-09-22
AU784488B2 (en) 2006-04-13
US20030036504A1 (en) 2003-02-20
EP1246638A1 (en) 2002-10-09
DE60105547T3 (de) 2014-12-31
DK1246638T3 (da) 2005-01-10
HK1050477A1 (en) 2003-06-27
AU2006202247A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PT1246638E (pt) Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
AR028512A1 (es) Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
UA82979C2 (ru) Фармацевтическая композиция, пригодная для перорального введения, которая содержит no-высвобождающие нспвл, лекарственная форма, фармацевтическая комбинация и способы лечения
PA8481401A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino
SV2003000886A (es) Agonistas de ppar ref. pc11023aado/bb
ES2196160T3 (es) Uso de una combinacion de tensioactivos, agentes quelantes y aceites esenciales para desinfeccion efectiva.
NO20090185L (no) Kontrollerte frigjoringsformuleringer
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
CO4970835A1 (es) Inhibicion de la oxidacion de lipoproteinas
WO2007012064A3 (en) Prevention and treatment of hearing disorders
AR054939A1 (es) Metodos para aplicar formulaciones antimicrobianas sobre alimentos
AR071183A1 (es) Composicion oral que comprende un componente activo y un componente formador de pelicula adhesiva, metodo
AR109263A2 (es) Composición que comprende moxidectina
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
WO2008128191A3 (en) Oral cephalotaxine dosage forms
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
CL2009000986A1 (es) Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma
ES2193185T3 (es) Formulacion farmaceutica para la prevencion o tratamiento previo de una intoxicacion con inhibidores de la colinesterasa organofosforados.
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
AU2203401A (en) Formulations of adenosine a1 agonists